The study compound is being developed for the treatment of heart failure. In this clinical trial, we investigate how the study compound is processed and eliminated by the body and how well it is tolerated when it is used by healthy participants.

Für Deutschland: Bitte beachten Sie: Die Arzneimittelstudien finden im niederländischen Groningen statt. Sie müssen Englisch oder Niederländisch sprechen, verstehen und lesen können, um an einer Studie teilnehmen zu können. 

• You are a healthy male or female.
• You are at least 18 and at most 55 years old.
• Your weight is at least 50 kg
• Your Body Mass Index (BMI) is:
  • at least 18 and at most 32 kg/m2 for part A, B and C.
  • at least 18 and at most 30 kg/m2 for part D. 
• Both non-smokers and light smokers or occasional smokers are allowed to participate in this clinical trial (maximum of 5 cigarettes per day). During your stay in our research facility, you are not allowed to smoke.

Note: 

• You cannot participate in the trial if you have participated in another clinical trial in the 30 days (about 4 and a half weeks) prior to the screening of this clinical trial (counting from the last dosing).
• To determine if you are suitable to participate in this trial, you will undergo a medical screening. 

As a female you can only participate if you meet one of the following conditions:

• You have passed menopause (no periods for at least 12 months);
• You have been sterilized or due to other reasons are sterile.

As a male you can only participate if you meet one of the following conditions;

• You are using a condom during sexual intercourse;
• You are not sexually active according to your lifestyle.

The trial consists of 4 parts: part A, part B, part C and part D. You can only participate in one part of this clinical trial.

Part A consists of 1 period during which you will stay in the research facility in Groningen (location van Swietenlaan 6) for 7 days (6 nights). The follow-up visit will take place on the day of your departure from the research facility. 21 to 27 days (about 4 weeks) after your departure from the research facility, you will be contacted by phone for some questions.

Part B consists of 1 period during which you will stay in the research facility in Groningen (location van Swietenlaan 6) for 13 days (12 nights). The follow-up visit will take place 4 to 5 days after your departure from the research facility. 20 to 26 days (about 3 and a half weeks) after the follow-up visit, you will be contacted by phone for some questions.

Part C consists of 1 period during which you will stay in the research facility in Groningen (location van Swietenlaan 6) for 16 days (15 nights). The follow-up visit will take place 4 to 5 days after your departure from the research facility. 20 to 26 days (about 3 and a half weeks) after the follow-up visit, you will be contacted by phone for some questions.

Part D consists of 1 period during which you will stay in the research facility in Groningen (location van Swietenlaan 6) for 20 days (19 nights). The follow-up visit will take place 3 to 4 days after your departure from the research facility. 21 to 27 days (about 4 weeks) after the follow-up visit, you will be contacted by phone for some questions.

Note: You must be available for all dates to be able to participate in this clinical trial.